1
|
Nishiki I, Yoshida T, Fujiwara A. Complete genome sequence and characterization of virulence genes in Lancefield group C Streptococcus dysgalactiae isolated from farmed amberjack (Seriola dumerili). Microbiol Immunol 2019; 63:243-250. [PMID: 31136000 DOI: 10.1111/1348-0421.12716] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2019] [Revised: 05/20/2019] [Accepted: 05/21/2019] [Indexed: 01/19/2023]
Abstract
Lancefield group C Streptococcus dysgalactiae causes infections in farmed fish. Here, the genome of S. dysgalactiae strain kdys0611, isolated from farmed amberjack (Seriola dumerili) was sequenced. The complete genome sequence of kdys0611 consists of a single chromosome and five plasmids. The chromosome is 2,142,780 bp long and has a GC content of 40%. It possesses 2061 coding sequences and 67 tRNA and 6 rRNA operons. One clustered regularly interspaced short palindromic repeat, 125 insertion sequences, and four predicted prophage elements were identified. Phylogenetic analysis based on 126 core genes suggested that the kdys0611 strain is more closely related to S. dysgalactiae subsp. dysgalactiae than to S. dysgalactiae subsp. equisimilis. The genome of kdys0611 harbors 87 genes with sequence similarity to putative virulence-associated genes identified in other bacteria, of which 57 exhibit amino acid identity (>52%) to genes of the S. dysgalactiae subsp. equisimilis GGS124 human clinical isolate. Four putative virulence genes, emm5 (FGCSD_0256), spg_2 (FGCSD_1961), skc (FGCSD_1012), and cna (FGCSD_0159), in kdys0611 did not show significant homology with any deposited S. dysgalactiae genes. The chromosomal sequence of kdys0611 has been deposited in GenBank under Accession No. AP018726. This is the first report of the complete genome sequence of S. dysgalactiae isolated from fish.
Collapse
Affiliation(s)
- Issei Nishiki
- Research Center for Bioinformatics and Biosciences, National Research Institute of Fisheries Science, Japan Fisheries Research and Education Agency, Yokohama, Kanagawa, Japan
| | | | - Atushi Fujiwara
- Research Center for Bioinformatics and Biosciences, National Research Institute of Fisheries Science, Japan Fisheries Research and Education Agency, Yokohama, Kanagawa, Japan
| |
Collapse
|
2
|
Takahashi K, Orito N, Tokunoh N, Inoue N. Current issues regarding the application of recombinant lactic acid bacteria to mucosal vaccine carriers. Appl Microbiol Biotechnol 2019; 103:5947-5955. [PMID: 31175431 DOI: 10.1007/s00253-019-09912-x] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2019] [Revised: 05/14/2019] [Accepted: 05/15/2019] [Indexed: 12/21/2022]
Abstract
Over the past two decades, lactic acid bacteria (LAB) have been intensively studied as potential bacterial carriers for therapeutic materials, such as vaccine antigens, to the mucosal tissues. LAB have several attractive advantages as carriers of mucosal vaccines, and the effectiveness of LAB vaccines has been demonstrated in numerous studies. Research on LAB vaccines to date has focused on whether antigen-specific immunity, particularly antibody responses, can be induced. However, with recent developments in immunology, microbiology, and vaccinology, more detailed analyses of the underlying mechanisms, especially, of the induction of cell-mediated immunity and memory cells, have been required for vaccine development and licensure. In this mini-review, we will discuss the issues, including (i) immune responses other than antibody production, (ii) persistence of LAB vaccine immunity, (iii) comparative evaluation of LAB vaccines with any existing or reference vaccines, (iv) strategies for increasing the effectiveness of LAB vaccines, and (iv) effects of microbiota on the efficacy of LAB vaccines. Although these issues have been rarely studied or discussed to date in relation to LAB vaccine research, further understanding of them is critical for the practical application of LAB vaccine systems.
Collapse
Affiliation(s)
- Keita Takahashi
- Department of Microbiology and Immunology, Gifu Pharmaceutical University, 1-25-4 Daigaku Nishi, Gifu, 501-1196, Japan.
| | - Nozomi Orito
- Department of Microbiology and Immunology, Gifu Pharmaceutical University, 1-25-4 Daigaku Nishi, Gifu, 501-1196, Japan
| | - Nagisa Tokunoh
- Department of Microbiology and Immunology, Gifu Pharmaceutical University, 1-25-4 Daigaku Nishi, Gifu, 501-1196, Japan
| | - Naoki Inoue
- Department of Microbiology and Immunology, Gifu Pharmaceutical University, 1-25-4 Daigaku Nishi, Gifu, 501-1196, Japan.
| |
Collapse
|
3
|
García PC, Paillavil BA, Scioscia N, Dale JB, Legarraga P, Salazar-Echegarai FJ, Bueno SM, Kalergis AM, Wozniak A. Clinical and microbiological response of mice to intranasal inoculation with Lactococcus lactis expressing Group A Streptococcus antigens, to be used as an anti-streptococcal vaccine. Microbiol Immunol 2019; 62:711-719. [PMID: 30357922 DOI: 10.1111/1348-0421.12657] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2018] [Revised: 10/22/2018] [Accepted: 10/22/2018] [Indexed: 11/28/2022]
Abstract
Protein subunit vaccines are often preferred because of their protective efficacy and safety. Lactic acid bacteria expressing heterologous antigens constitute a promising approach to vaccine development. However, their safety in terms of toxicity and bacterial clearance must be evaluated. Anti-Streptococcus pyogenes (S. pyogenes) vaccines face additional safety concerns because they may elicit autoimmune responses. The assessment of toxicity, clearance and autoimmunity of an anti-streptococcal vaccine based on Lactococcus lactis (L. lactis) expressing 10 different M protein fragments from S. pyogenes (L. lactis-Mx10) is here reported. Clearance of L. lactis from the oropharynges of immunocompetent mice and mice devoid of T/B lymphocytes mice was achieved without using antibiotics. The absence of autoimmune responses against human tissues was demonstrated with human brain, heart and kidney. Assessment of toxicity showed that leucocyte counts and selected serum biochemical factors were not affected in L. lactis-Mx10-immunized mice. In contrast, mice immunized with L. lactis wild type vector (L. lactis-WT) showed increased neutrophil and monocyte counts and altered histopathology of lymph nodes, lungs and nasal epithelium. Two days after immunization, L. lactis-Mx10-immunized and L. lactis-WT-immunized mice weighed significantly less than unimmunized mice. However, both groups of immunized mice recovered their body weights by Day 6. Our results demonstrate that L. lactis-WT, but not the vaccine L. lactis-Mx10, induces alterations in certain hematologic and histopathological variables. We consider these data a major contribution to data on L. lactis as a bacterial vector for vaccine delivery.
Collapse
Affiliation(s)
- Patricia C García
- Laboratory of Microbiology, Department of Clinical Laboratories, School of Medicine, Pontifical Catholic University of Chile, Santiago 8331010, Chile
| | - Braulio A Paillavil
- Laboratory of Microbiology, Department of Clinical Laboratories, School of Medicine, Pontifical Catholic University of Chile, Santiago 8331010, Chile
| | - Natalia Scioscia
- Laboratory of Microbiology, Department of Clinical Laboratories, School of Medicine, Pontifical Catholic University of Chile, Santiago 8331010, Chile
| | - James B Dale
- Department of Medicine, University of Tennessee Health Science Center and the Department of Veterans Affairs Medical Center, Memphis, TN 38163, USA
| | - Paulette Legarraga
- Laboratory of Microbiology, Department of Clinical Laboratories, School of Medicine, Pontifical Catholic University of Chile, Santiago 8331010, Chile
| | - Francisco J Salazar-Echegarai
- Department of Molecular Genetics and Microbiology, School of Biological Sciences, Millennium Institute on Immunology and Immunotherapy, Pontifical Catholic University of Chile, Santiago 8331010, Chile
| | - Susan M Bueno
- Department of Molecular Genetics and Microbiology, School of Biological Sciences, Millennium Institute on Immunology and Immunotherapy, Pontifical Catholic University of Chile, Santiago 8331010, Chile
| | - Alexis M Kalergis
- Department of Molecular Genetics and Microbiology, School of Biological Sciences, Millennium Institute on Immunology and Immunotherapy, Pontifical Catholic University of Chile, Santiago 8331010, Chile.,Department of Endocrinology, School of Medicine, Pontifical Catholic University of Chile, Santiago 8331010, Chile
| | - Aniela Wozniak
- Laboratory of Microbiology, Department of Clinical Laboratories, School of Medicine, Pontifical Catholic University of Chile, Santiago 8331010, Chile.,Department of Endocrinology, School of Medicine, Pontifical Catholic University of Chile, Santiago 8331010, Chile
| |
Collapse
|
4
|
Wozniak A, Scioscia N, García PC, Dale JB, Paillavil BA, Legarraga P, Salazar-Echegarai FJ, Bueno SM, Kalergis AM. Protective immunity induced by an intranasal multivalent vaccine comprising 10 Lactococcus lactis strains expressing highly prevalent M-protein antigens derived from Group A Streptococcus. Microbiol Immunol 2018; 62:395-404. [PMID: 29704396 PMCID: PMC6013395 DOI: 10.1111/1348-0421.12595] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2018] [Revised: 04/13/2018] [Accepted: 04/19/2018] [Indexed: 11/28/2022]
Abstract
Streptococcus pyogenes (group A Streptococcus) causes diseases ranging from mild pharyngitis to severe invasive infections. The N-terminal fragment of streptococcal M protein elicits protective antibodies and is an attractive vaccine target. However, this N- terminal fragment is hypervariable: there are more than 200 different M types. In this study, an intranasal live bacterial vaccine comprising 10 strains of Lactococcus lactis, each expressing one N-terminal fragment of M protein, has been developed. Live bacterial-vectored vaccines cost less to manufacture because the processes involved are less complex than those required for production of protein subunit vaccines. Moreover, intranasal administration does not require syringes or specialized personnel. Evaluation of individual vaccine types (M1, M2, M3, M4, M6, M9, M12, M22, M28 and M77) showed that most of them protected mice against challenge with virulent S. pyogenes. All 10 strains combined in a 10-valent vaccine (M×10) induced serum and bronchoalveolar lavage IgG titers that ranged from three- to 10-fold those of unimmunized mice. After intranasal challenge with M28 streptococci, survival of M×10-immunized mice was significantly higher than that of unimmunized mice. In contrast, when mice were challenged with M75 streptococci, survival of M×10-immunized mice did not differ significantly from that of unimmunized mice. Mx-10 immunized mice had significantly less S. pyogenes in oropharyngeal washes and developed less severe disease symptoms after challenge than did unimmunized mice. Our L. lactis-based vaccine may provide an alternative solution to development of broadly protective group A streptococcal vaccines.
Collapse
MESH Headings
- Administration, Intranasal/methods
- Animals
- Antibodies, Bacterial/blood
- Antigens, Bacterial/classification
- Antigens, Bacterial/immunology
- Antigens, Bacterial/metabolism
- Bacterial Outer Membrane Proteins/classification
- Bacterial Outer Membrane Proteins/immunology
- Bacterial Outer Membrane Proteins/metabolism
- Body Weight
- Carrier Proteins/classification
- Carrier Proteins/immunology
- Carrier Proteins/metabolism
- Disease Models, Animal
- Female
- Immunity
- Immunization
- Immunoglobulin G/blood
- Lactococcus lactis/immunology
- Lactococcus lactis/pathogenicity
- Mice
- Mice, Inbred BALB C
- Streptococcal Infections/immunology
- Streptococcal Infections/microbiology
- Streptococcal Infections/prevention & control
- Streptococcal Vaccines/administration & dosage
- Streptococcal Vaccines/immunology
- Streptococcus pyogenes/immunology
- Treatment Outcome
- Vaccination/methods
- Vaccines, Attenuated/administration & dosage
- Vaccines, Attenuated/immunology
- Vaccines, Synthetic/administration & dosage
- Vaccines, Synthetic/immunology
Collapse
Affiliation(s)
- Aniela Wozniak
- Laboratorio de Microbiología, Departamento de Laboratorios Clínicos, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago 7820436, Chile
| | - Natalia Scioscia
- Laboratorio de Microbiología, Departamento de Laboratorios Clínicos, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago 7820436, Chile
| | - Patricia C. García
- Laboratorio de Microbiología, Departamento de Laboratorios Clínicos, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago 7820436, Chile
| | - James B. Dale
- Department of Medicine, University of Tennessee Health Science Center and the Department of Veterans Affairs Medical Center, Memphis, Tennessee, TN 38163, USA
| | - Braulio A. Paillavil
- Laboratorio de Microbiología, Departamento de Laboratorios Clínicos, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago 7820436, Chile
| | - Paulette Legarraga
- Laboratorio de Microbiología, Departamento de Laboratorios Clínicos, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago 7820436, Chile
| | - Francisco J. Salazar-Echegarai
- Millennium Institute on Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Susan M. Bueno
- Millennium Institute on Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Alexis M. Kalergis
- Millennium Institute on Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
- Departamento de Endocrinología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago 8331010, Chile
| |
Collapse
|
5
|
Zhang X, Song Y, Li Y, Cai M, Meng Y, Zhu H. Immunization with Streptococcal Heme Binding Protein (Shp) Protects Mice Against Group A Streptococcus Infection. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2017; 973:115-124. [PMID: 28190144 DOI: 10.1007/5584_2016_198] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Streptococcal heme binding protein (Shp) is a surface protein of the heme acquisition system that is an essential iron nutrient in Group A Streptococcus (GAS). Here, we tested whether Shp immunization protects mice from subcutaneous infection. Mice were immunized subcutaneously with recombinant Shp and then challenged with GAS. The protective effects against GAS challenge were evaluated two weeks after the last immunization. Immunization with Shp elicited a robust IgG response, resulting in high anti-Shp IgG titers in the serum. Immunized mice had a higher survival rate and smaller skin lesions than adjuvant control mice. Furthermore, immunized mice had lower GAS numbers at the skin lesions and in the liver, spleen and lung. Histological analysis with Gram staining showed that GAS invaded the surrounding area of the inoculation sites in the skin in control mice, but not in immunized mice. Thus, Shp immunization enhances GAS clearance and reduces GAS skin invasion and systemic dissemination. These findings indicate that Shp is a protective antigen.
Collapse
Affiliation(s)
- Xiaolan Zhang
- Department of Physiology, the college of Basic, Medical Sciences, Harbin Medical University, Harbin, China
| | - Yingli Song
- Department of Physiology, the college of Basic, Medical Sciences, Harbin Medical University, Harbin, China
| | - Yuanmeng Li
- Department of Physiology, the college of Basic, Medical Sciences, Harbin Medical University, Harbin, China
| | - Minghui Cai
- Department of Physiology, the college of Basic, Medical Sciences, Harbin Medical University, Harbin, China
| | - Yuan Meng
- Department of Physiology, the college of Basic, Medical Sciences, Harbin Medical University, Harbin, China
| | - Hui Zhu
- Department of Physiology, the college of Basic, Medical Sciences, Harbin Medical University, Harbin, China.
| |
Collapse
|